NCT01163903已完成1 期
A Phase I Study Evaluating the Proton Pump Inhibitor Pantoprazole in Combination With Doxorubicin for Advanced Cancer Patients With an Extension Cohort of Patients With Solid Tumours
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Determination of recommended phase II dose (RP2D) of pantoprazole given with doxorubicin at 60mg/m2
研究概览
简要总结
This is a single-centre, open label, dose finding, phase I study to determine the recommended phase II dose (RP2D) for the combination of doxorubicin and pantoprazole in patients with advanced tumours and no standard treatment options. A minimum of 3 patients will be enrolled per dose level and intra-patient dose escalation is not permitted. Once the RP2D has been identified, six additional patients with metastatic solid tumours will be treated at the RP2D to confirm its tolerability.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically proven advanced solid tumours for whom no standard anticancer therapy exists
- •Measureable and non-measureable disease are both eligible, but disease must be evaluable as defined by RECIST 1.
- •Patients >18 years old
- •At least 21 days since last chemotherapy regimen and/or radiotherapy
- •Recovery from all reversible adverse events of previous anticancer therapies to baseline or to grade < or =1, except for alopecia.
- •Patients must have documented evidence of disease progression on prior systemic therapy.
- •ECOG Performance Status of 0 or 1
- •Adequate cardiovascular function and no history of serious cardiac diseases (see Exclusion criteria for definition) Left ventricular ejection fraction > 50% by multi-gated nuclear angiogram
- •Patient consent must be obtained according to Institutional REB requirements. The patient must sign the consent form prior to registration.
- •Patients must be accessible for treatment and follow-up.
- •Previous Therapy
- •Chemotherapy: Patients can have had limited exposure to prior anthracyclines defined as no more than a total dose of 240 mg/m2 of doxorubicin or 300 mg/m2 of epirubicin (e.g. as received in the AC x 4 or FEC x 3 adjuvant regimens). Patients with prior exposure to other cardiotoxic anticancer drugs (e.g. mitoxantrone) are not eligible.
- •Radiation: Patients may have had prior radiation therapy (including that to the breast or chest wall) provided that has not exceeded 25% of the bone marrow reserve.
- •Previous Surgery: Previous surgery is permitted provided that wound healing has occurred.
- •Hormonal Therapy: Patients may have had prior hormonal therapy. All hormonal agents must be discontinued at least 3 weeks prior to study entry.
- •Laboratory Requirements (must be done within 7 days prior to registration)
- •Neutrophil count (ANC) > or = 1.5 x 10^9/L
- •Hemoglobin > or = 90 g/L
- •Platelet count > or = 100 x 10^9/L
- •Bilirubin <1.5 x UNL
- •AST or ALT < or = 2 x UNL
- •Creatinine < or = 1.5 x UNL or creatinine clearance > or = 50mL/min
排除标准
- •Patients who have previously received more than 240 mg/m2 doxorubicin or 300 mg/m2 epirubicin.
- •Patients receiving concurrent treatment with experimental drugs or anti-cancer therapy.
- •Patients who are receiving drugs that are known to interact with pantoprazole, including:
- •The anti-fungal agents fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole;
- •The antiviral agents: atazanavir, delavirdine, indinavir, nelfinavir, raltegravir, saquinavir, tipranavir;
- •The anticoagulant agents: clopidogrel, dabigatran;
- •The immunosuppressive agent: mycophenolate
- •The anti-inflammatory agent: mesalamine
- •Patients who are receiving oral pantoprazole or other PPI inhibitors may participate if these agents are discontinued at least 7 days before trial entry.
- •Patients with untreated brain or meningeal metastases. (MR or CT scans are not required to rule this out unless there is a clinical suspicion of CNS disease). Patients with treated and stable brain metastases are eligible providing that they have radiological evidence of disease stabilization of at least 3 months duration and are asymptomatic.
- •Patients who have a history of clinically significant cardiac disease, including:
- •Unstable angina/ acute coronary syndrome
- •Congestive heart failure
- •Myocardial infarction within the past year
- •Clinically significant arrhythmia
- •Pericarditis or myocarditis
- •Symptomatic valvular disease Patients with well-controlled hypertension, uncomplicated mitral valve prolapsed or other stable cardiac conditions are eligible.
- •Patients with active or uncontrolled infections or with serious illnesses or medical conditions that would not permit the patient to be managed according to the protocol.
- •Patients with a known bleeding disorder. Patients who are on stable anticoagulation with warfarin or s.c. heparin products are eligible. Patients receiving clopidogrel are excluded.
- •Patients unable or unwilling to give written, informed consent prior to study participation.
- •Women who are pregnant or nursing.
研究组 & 干预措施
Pantoprazole and doxorubicin
Experimental
干预措施: pantoprazole sodium for injection (Drug)
Pantoprazole and doxorubicin
Experimental
干预措施: doxorubicin hydrochloride injection (Drug)
结局指标
主要结局
Determination of recommended phase II dose (RP2D) of pantoprazole given with doxorubicin at 60mg/m2
时间窗: Treatment until documented progression or up to 8 21-day cycles (4 cycles if prior anthracyclines received). All patients followed for late toxicities, every 3 months for 1 year or until all drug related toxicities are resolved/become unrelated.
To determine the recommended phase II dose (RP2D) of pantoprazole given with doxorubicin at 60mg/m2 when administered to adult patients with advanced solid tumours.
次要结局
- Characterize the safety and tolerability of the combination by determining dose-limiting toxicities (DLTs). Toxicities evaluated and graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.(Treatment until documented progression or up to 8 21-day cycles (4 cycles if prior anthracyclines received). All patients followed for late toxicities, every 3 months for 1 year or until all drug related toxicities are resolved/become unrelated.)
- Assess the preliminary anti-tumour activity of the doxorubicin/pantoprazole by combination in patients with advanced solid tumours, by evaluating tumour response rate.(Radiologic evaluation (CT scan of chest, abdomen and pelvis) performed every 9 weeks)
- Evaluate the pharmacokinetics of doxorubicin and pantoprazole when given in combination by collecting venous blood samples at various timepoints throughout study drug administration.(Blood samples just before and at the end of pantoprazole and doxorubicin administration, and at 1, 2, 4, 8, 24, 48 and 72 hours after (first or second) drug administration for evaluation of serum levels of doxorubicin and pantoprazole)
- Evaluate (in selected patients with lesions amenable to biopsy) the influence of pantoprazole on distribution of doxorubicin in tumour tissue. Tumour tissue extracted after administration of doxorubicin/pantoprazole.(Tumour biopsy within 24-48h after administration of doxorubicin (in consenting patients with disease amenable to biopsy))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy ParticipantsHealthy VolunteerNCT06264440Biogen18
已完成
1 期
A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine VepdegestrantHealthyNCT06275841Pfizer12
招募中
2 期
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock PatientsAcute Kidney InjuryNCT06531642The University of Texas Health Science Center, Houston100
撤回
1 期
Proton Therapy With Capecitabine for Rectal CancerRectal CancerNCT00503932M.D. Anderson Cancer Center
尚未招募
1 期
A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid TumorsPatients With Advanced Solid TumorsNCT05370755Beijing InnoCare Pharma Tech Co., Ltd.22